Active, Not Recruiting
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
NCT05290597
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
- Locations
-
- [email protected] Sydney, New South Wales, Australia
- Westmead Hospital Sydney, New South Wales, Australia
- Sydney Southwest Private Hospital Sydney, New South Wales, Australia
- Cancer Care Wollongong Sydney, New South Wales, Australia